×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Kristie L. Kahl
Researchers evaluates microsatellite instability-high status, tumor mutation burden and high PD-L1 expression to determine which grade of tumors would benefit from immunotherapy treatment among women with endometrioid endometrial cancer.
Brielle Urciuoli
The Food and Drug Administration (FDA) approved a next-generation sequencing (NGS) companion diagnostic assay that can detect BRCA1/2 genetic mutations, as well as the percentage of genomic loss of heterozygosity (LOH) in patients with ovarian cancer.
Kristie L. Kahl
Albeit growing popularity of at-home genetic testing, it is still necessary to seek professional medical opinions from genetic counselors to help discuss results.
Kristie L. Kahl
After an infection that was a result from her aggressive chemotherapy treatment, Joan Lunden and three breast cancer survivors took to the stage at Cancer Con to help others learn about these risks and how to best advocate for themselves during their discussions with their doctors.
Brielle Urciuoli
In particular, patients whose tumors have certain genetic mutations may respond especially well to this combination approach.
Brielle Urciuoli
There are a number of different treatment options for patients with relapsed myeloma, and it is important that patients and providers dicuss health history to determine which one is best.
Brielle Urciuoli
For patients with melanoma, administration of a PD-1 checkpoint blockade therapy in the neoadjuvant setting – meaning it was given before the main treatment – could result in improved outcomes and better insight to patient responses. 
The Food and Drug Administration (FDA) approved Tagrisso as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor EGFR mutations.
Jason M. Broderick
The Food and Drug Administration (FDA) granted priority review to a supplemental biologics license application for Opdivo (nivolumab) for the treatment of patients with small cell lung cancer with disease progression following two or more lines of therapy.
Brielle Urciuoli
After being diagnosed with a rare cancer, professional runner Gabriele Grunewald became inspired to start a nonprofit that raised awareness for other rare cancers and empowered those who have them.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable